After hours: December 17 at 5:41:26 PM EST Loading Chart for TAK ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£37.96 Analyst price target for HIK is US$23.28 which is 39% below our fair value estimate In this ...
Hikma Pharmaceuticals PLC HIK shares inched down 0.51% to £19.54 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0. ...
在全球制药行业中,Hikma药业无疑是一个闪亮的名字。自1978年在约旦创立以来,Hikma在仿制药领域崭露头角,2021年的总销售额高达25.53亿美元,成为行业中的佼佼者。那么,Hikma究竟凭借什么成功逆袭到今天的辉煌地位?本文将揭示Hikma仿制药企业的成功秘籍 ...
Takeda's recently approved advanced colorectal cancer therapy Fruzaqla has been rejected by NICE for use by the NHS on the grounds that it is not cost-effective. In draft guidance (PDF), the ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Shares of Hikma Pharmaceuticals PLC HIK inched up 0.52% to £19.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0. ...
Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.